Klara Grantz Saskova

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8557502/publications.pdf

Version: 2024-02-01

20	815	516561 16	752573 20
papers	citations	h-index	g-index

22	22	22	1049
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Design of HIV Protease Inhibitors Based on Inorganic Polyhedral Metallacarboranes. Journal of Medicinal Chemistry, 2009, 52, 7132-7141.	2.9	132
2	Inorganic Polyhedral Metallacarborane Inhibitors of HIV Protease: A New Approach to Overcoming Antiviral Resistance. Journal of Medicinal Chemistry, 2008, 51, 4839-4843.	2.9	90
3	Molecular Analysis of the HIV-1 Resistance Development: Enzymatic Activities, Crystal Structures, and Thermodynamics of Nelfinavir-resistant HIV Protease Mutants. Journal of Molecular Biology, 2007, 374, 1005-1016.	2.0	74
4	Structure-Aided Design of Novel Inhibitors of HIV Protease Based on a Benzodiazepine Scaffold. Journal of Medicinal Chemistry, 2012, 55, 10130-10135.	2.9	53
5	Thermodynamic and structural analysis of <scp>HIV</scp> protease resistance to darunavirÂâ€“Âanalysis of heavily mutated patientâ€derived <scp>HIV</scp>â€ proteases. FEBS Journal, 2014, 281, 1834-1847.	2.2	48
6	Human DNA-Damage-Inducible 2 Protein Is Structurally and Functionally Distinct from Its Yeast Ortholog. Scientific Reports, 2016, 6, 30443.	1.6	46
7	Structural studies of the yeast DNA damage-inducible protein Ddi1 reveal domain architecture of this eukaryotic protein family. Scientific Reports, 2016, 6, 33671.	1.6	44
8	Molecular Characterization of Clinical Isolates of Human Immunodeficiency Virus Resistant to the Protease Inhibitor Darunavir. Journal of Virology, 2009, 83, 8810-8818.	1.5	43
9	Mutations in HIV-1gagandpolCompensate for the Loss of Viral Fitness Caused by a Highly Mutated Protease. Antimicrobial Agents and Chemotherapy, 2012, 56, 4320-4330.	1.4	40
10	Ninety-Nine Is Not Enough: Molecular Characterization of Inhibitor-Resistant Human Immunodeficiency Virus Type 1 Protease Mutants with Insertions in the Flap Region. Journal of Virology, 2008, 82, 5869-5878.	1.5	39
11	Specific Inhibitors of HIV Capsid Assembly Binding to the C-Terminal Domain of the Capsid Protein: Evaluation of 2-Arylquinazolines as Potential Antiviral Compounds. Journal of Medicinal Chemistry, 2016, 59, 545-558.	2.9	39
12	The yeast proteases Ddi1 and Wss1 are both involved in the DNA replication stress response. DNA Repair, 2019, 80, 45-51.	1.3	31
13	Quantitative proteomics reveals neuronal ubiquitination of Rngo/Ddi1 and several proteasomal subunits by Ube3a, accounting for the complexity of Angelman syndrome. Human Molecular Genetics, 2018, 27, 1955-1971.	1.4	30
14	Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir. Protein Science, 2008, 17, 1555-1564.	3.1	24
15	Nelfinavir Inhibits the TCF11/Nrf1-Mediated Proteasome Recovery Pathway in Multiple Myeloma. Cancers, 2020, 12, 1065.	1.7	23
16	Capturing a dynamically interacting inhibitor by paramagnetic NMR spectroscopy. Physical Chemistry Chemical Physics, 2019, 21, 5661-5673.	1.3	21
17	Lipid Nanoparticles for Broadâ€Spectrum Nucleic Acid Delivery. Advanced Functional Materials, 2021, 31, 2101391.	7.8	13
18	GS-8374, a Prototype Phosphonate-Containing Inhibitor of HIV-1 Protease, Effectively Inhibits Protease Mutants with Amino Acid Insertions. Journal of Virology, 2014, 88, 3586-3590.	1.5	9

#	ARTICLE	IF	CITATIONS
19	Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies. Antiviral Research, 2008, 78, 275-277.	1.9	7
20	Backbone 1H, 13C, and 15N NMR assignment for the inactive form of the retroviral protease of the murine intracisternal A-type particle, inMIA-14 PR. Biomolecular NMR Assignments, 2009, 3, 261-264.	0.4	4